Replies to post #194963 on Biotech Values

[DewDiligence]

AGTC receives EMA ODD for achromatopsia:

http://finance.yahoo.com/news/agtc-announces-orphan-drug-designation-110100476.html

The ODD refers to AGTC’s program pertaining to mutations in the CNGA3 gene, but not to the program for mutations in the CNGB3 gene.

[DewDiligence]

AGTC had $199.3M of cash at 9/30/15—sufficient (the company says) for at least two years:

http://www.sec.gov/Archives/edgar/data/1273636/000156459015009654/agtc-ex991_43.htm

Based on AGTC’s strong cash position of $199 million as of September 30, 2015, the company expects to have sufficient cash for at least the next two years for the completion of the ongoing phase 1/2 human clinical trial for XLRS and the planned phase 1/2 human clinical trial for ACHM. AGTC also expects to be able to fund pre-clinical research and the initiation and complete enrollment of human clinical trials for a second form of ACHM and for the company’s partnered program to treat X-linked Retinitis Pigmentosa (XLRP).

Operating cash burn in 3Q15 was $15M, excluding the $129M in payments received from BIIB (#msg-116884614).